FORMULATION AND INVITRO EVALUATION OF GLICLAZIDE FLOATING PULSATILE DRUG DELIVERY SYSTEM

Drug delivery systems based on chronotherapy are designed to facilitate medication release with circadian rhythm-dependent medical conditions such non-insulin-dependent diabetic mellitus (NIDDM). An acceptable choice for pulsatile administration to treat early-morning hyperglycemia is gliclazide, a short-acting sulfonylurea. The goal of the current study was to create and assess a time-dependent floating pulsatile drug delivery system for gliclazide that offers a predetermined lag time followed by quick drug release. Superdisintegrants such as sodium starch glycolate, crospovidone XL, and croscarmellose sodium were incorporated in the formulation of a rapid-release core tablet. While floating layers have been developed by press-coating low-density polymers like Carbomer 974P and HPMC E15LV, time-dependent barrier layers were created using several grades of HPMC (K4M, K15M, and K100M). The physicochemical characteristics, drug content, in vitro buoyancy, dissolving behavior, release kinetics, and stability of the formulations had been evaluated. FTIR analyses established the absence of drug-excipient incompatibility. Within five minutes, core formulation T6 confirmed significant drug release. The improved floating pulsatile formulation (F5P6T6) demonstrated a burst release of more than 80%, a consistent lag time of 5–8 hours, as well as adequate buoyancy. The Korsmeyer-Peppas model was followed by drug release, suggesting anomalous transport. Studies on stability revealed no notable improvements. A promising chronopharmaceutical technique to achieve successful NIDDM control has been proved by the established system.